Treatment strategies to reverse efflux transporter-mediated resistance to Tyrosine kinase inhibitors
Multidrug resistance (MDR), a phenomenon in which tumors that were initially sensitive, recur and start showing resistance not only to the initial chemotherapeutic agent but also to various anticancer drugs that are structurally and functionally different from the initial drug, constitutes one of th...
Main Author: | D'Cunha, Ronilda Raymond |
---|---|
Other Authors: | An, Guohua |
Format: | Others |
Language: | English |
Published: |
University of Iowa
2018
|
Subjects: | |
Online Access: | https://ir.uiowa.edu/etd/6563 https://ir.uiowa.edu/cgi/viewcontent.cgi?article=8062&context=etd |
Similar Items
-
Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro
by: Johanna Weiss, et al.
Published: (2014-12-01) -
Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective
by: Eleonora Russo, et al.
Published: (2021-06-01) -
Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection—A pharmacovigilance analysis
by: Michael Dörks, et al.
Published: (2021-02-01) -
Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor ponatinib
by: Diana Corallo, et al.
Published: (2020-09-01) -
Tyrosine kinase – Role and significance in Cancer
Published: (2004-06-01)